<DOC>
	<DOCNO>NCT00151801</DOCNO>
	<brief_summary>Clinical experimental evidence suggest immunomodulatory effect sex hormone multiple sclerosis . The role oral estroprogestins pathogenesis clinical course disease actually unknown . The aim study investigate safety tolerability association estroprogestins two different dos interferon-beta 1a patient relapsing-remitting multiple sclerosis .</brief_summary>
	<brief_title>Safety Tolerability Interferon-Beta-1a Estroprogestins Association MS Patients</brief_title>
	<detailed_description>Phase 2 , randomise , single blind , three arm study . Follow-up 24 month . The study include relapsing-remitting multiple sclerosis female patient . Patients equally randomise three group : 1 ) patient treat IFN-beta 1a ( 44 mcg three time week ) , 2 ) patient treat IFN-beta 1a lower-dose estroprogestins ( desogestrel 150 mcg , etinilestradiol 20 mcg ) , 3 ) patient treat IFN-beta 1a higher-dose estroprogestins ( desogestrel 25 mcg , etinilestradiol 40 mcg ) . Safety tolerability treatment evaluate use neurological examination MRI analysis . A complete neurological examination ( EDSS ) perform month 0 , 6 , 12 , 18 24 . MRI examination assess baseline month 12 24 . In day MRI examination 'll collect blood sample hormonal analysis ( 'll measure sex hormone follicular luteal phase single menstrual cycle ) . During follow-up patient evaluate also : MS-Functional Composite month 0 , 6 , 12 , 18 , 24 ; neuropsychological evaluation month 0 , 12 , 24 ; Fatigue Severity Scale month 0 , 12 , 24 ; Hamilton Depression Scale month 0 , 12 , 24 ; Quality Life scale ( MSQOL54 ) month 0 , 12 , 24 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Female patient Clinically definite relapsingremitting MS accord McDonald criterion Age 1840 y.o . EDSS 0 4.0 , inclusive History migraine thromboembolic event Reproductive system disorder Pregnancy suspension pregnancy within 12 month prior randomisation Prior use estroprogestins within last 3 month prior randomisation Prior use immunosuppressive drug within last 12 month prior randomisation Prior use immunomodulating drug within last 6 month prior randomisation Prior use corticosteroid within last 3 month prior randomisation Have clinical relapse 30 day prior randomisation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>estroprogestins</keyword>
	<keyword>interferon-beta</keyword>
	<keyword>sex hormone</keyword>
	<keyword>MRI</keyword>
</DOC>